New drug cocktail tested for aggressive blood cancer
NCT ID NCT00378105
Summary
This study is testing a combination of three drugs—bortezomib, lenalidomide, and dexamethasone—for people newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goals are to find the safest dose of the drug combination and to see how well it works to control the disease. Participants receive the drugs in 21-day cycles and may continue on a maintenance schedule if they respond well after the initial treatment period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.